

Curriculum vitae

Uwe Haberkorn Prof. Dr. med.

Education

1979-82 Studies in Philosophy and German literature at the University of Heidelberg
1982-88 Studies in medicine at the universities of Marburg, Würzburg and Heidelberg
1985 - 88 M.D. correlation of ultrasound image pattern and liver tissue properties in excised livers
1988-98 Research physician at the department of Oncological Diagnostics and therapy (Prof. Dr. G. van Kaick) at the DKFZ Heidelberg
1995 Board Nuclear medicine
1996 Habilitation thesis
since 1998 Professor of Nuclear medicine at the University of Heidelberg, Head of the Dept. of Nuclear Medicine, University of Heidelberg, Head of the Clinical Cooperation Unit Nuclear Medicine at the Deutsches Krebsforschungszentrum Heidelberg

Selected Awards

1996 Mallinckrodt price of the German Society for Nuclear Medicine
1996 Haberkorn U, Oberdorfer F, Gebert J, Morr I, Haack K, Weber K, Lindauer M, Kaick G van, Schackert HK. Monitoring of gene therapy with cytosine deaminase: in vitro studies with 3H-5-fluorocytosine. J Nucl Med;37:87-94
1998. 1. award for contrast media research to G. Brix, M.E. Bellemann and U. Haberkorn for "Intra- and Extracellular 5-Fluorouracil Uptake in Rats with Morris Hepatoma as Detected with Contrast-Enhanced Metabolic ¹⁹F MR Imaging". German Society of Radiology
2006 Von Hevesy award of the German Society for Nuclear Medicine: Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Vorwald S, Eskerski H, Eisenhut M, Metz J, Kinscherf R, Haberkorn U. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin Cancer Res 2005; 11:2132-2140.
2017 Wil de Jongh medal of the Federal Association of the Prostate Carcinoma Interest Groups
2017 Marie Curie Lecture annual meeting of the European Association of Nuclear Medicine (EANM)
2017 Marie Curie award annual meeting of the European Association of Nuclear Medicine (EANM)
2018 Schrödinger award of the Helmholtz-Society with Michael Eisenhut-Matthias Eder and Klaus Kopka
since 2020 Member of the Leopoldina
2020, 2021, 2022, 2023 Highly rated researcher Clarivate Web of Science

Editorial Board:

Nuklearmedizin, Molecular Imaging, Molecular Imaging & Biology, European Journal of Nuclear Medicine (2002), Technology in Cancer Research and Treatment

Reviewer:

Dutch Cancer Society, Wilhelm Sanders Stiftung, DFG, German-Israeli Foundation, MRC Medical Research Council London UK, Mildred Scheel Stiftung

Journals:

since 1991 Journal of Nuclear Medicine,
since 1996 Radiologe,
since 1997 Nuclear Medicine and Biology
since 1998 International Journal of Oncology
since 1998 Nature Medicine
since 1999 European Journal of Clinical Investigation
since 1999 Der Chirurg
since 1999 J Cancer Res Clin Oncol
since 1999 Int J Cancer
since 2001 Journal of Endocrinology
since 2002 Journal of Molecular Endocrinology
since 2002 PNAS

Board (selection)

Since 11/2004 Consultant of the 'Institut national de la santé et de la recherche médicale' (INSERM)
11/2004 Consultant at the IAEA Vienna
Since 2005 Consultant at the Institut national du cancer (INCA) Paris
Consultant Agence national de la Recherche (ANR) Frankreich
Consultant GIS IBISA Paris
Scientific advisory board Arronax Nantes

Top 10 publications

1. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U. The diagnostic value of PET/CT imaging with the ⁶⁸Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 2015;42:197-209.
2. Altmann A, Sauter M, Roesch S, Mier W, Warta R, Debus J, Dyckhoff G, Herold-Mende C, Haberkorn U. Identification of a novel ITGavb6-binding peptide using protein separation and phage display. *Clin Cancer Res*;23:4170-4180.
3. Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, J.ger D, Flechsig P, Altmann A, Mier W, Haberkorn U. ⁶⁸Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. *J Nucl Med*. 2019;60:386-392.
4. Kratochwil C, Giesel FL, Stefanova M, Benešov. M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617. *J Nucl Med*. 2016;57:1170-6.
5. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, R.hrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, J.ger D, Debus J, Haberkorn U, Giesel FL. ⁶⁸Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. *J Nucl Med*. 2019;60:801-805.

6. Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, Jäger D, Mier W, Haberkorn U. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. *J Nucl Med.* 2018;59:1415-1422.
7. Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jäger D, Giesel F, Kratochwil C, Barthe P, Roumestand C, Haberkorn U. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. *J Nucl Med.* 2018;59:1423-1429
8. Roesch S, Lindner T, Sauter M, Loktev A, Flechsig P, Müller M, Mier W, Warta R, Dyckhoff G, Herold-Mende C, Haberkorn U, Altmann A. Comparison of the RGD Motif-Containing $\alpha\beta6$ Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. *J Nucl Med.* 2018;59:1679-1685.
9. Zoller F, Markert A, Barthe P, Zhao W, Askoxylakis V, Altmann A, Mier W, Haberkorn U. Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumortargeting Mini-proteins. *Angewandte Chemie Int Edition.* 2012;51:13136-9.
10. Zoller F, Markert A, Barthe P, Hebling U, Altmann A, Lindner T, Mier W, Haberkorn U. A Disulfide-Constrained Mini-protein with Striking Tumor-Binding Specificity Developed by Ribosome Display. *Angewandte Chemie Int Edition* 2013; 52: 11760-11764.